Interestingly, the recent network meta-analysis by Haeussler and colleagues in 2022 assessed the comparative effectiveness and safety profiles for multiple first-line treatment options indicated for advanced EGFR mutation-positive NSCLC clinical cases [25]. Here, EGFR is linked to non-small cell lung carcinoma.